[{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Constellation Alpha Holdings","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Constellation Alpha Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Constellation Alpha Holdings"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Oberland Capital Management"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intra-arterial Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Humacyte","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0.050000000000000003,"dosageForm":"Intra-arterial Implant","sponsorNew":"Humacyte \/ TD Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Humacyte \/ TD Cowen"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humacyte \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ FGK Clinical Research"},{"orgOrder":0,"company":"Humacyte","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ TD Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ TD Cowen"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"EF Hutton","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ EF Hutton","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ EF Hutton"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Humacyte
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
